Search hospitals > Texas > Dallas
Baylor University Medical Center
Claim this profileDallas, Texas 75246
Global Leader in Adult T-Cell Leukemia/Lymphoma
Global Leader in Lymphoma
Conducts research for Myeloid Leukemia
Conducts research for Heart Failure
Conducts research for Acute Myeloid Leukemia
357 reported clinical trials
17 medical researchers
Summary
Baylor University Medical Center is a medical facility located in Dallas, Texas. This center is recognized for care of Adult T-Cell Leukemia/Lymphoma, Lymphoma, Myeloid Leukemia, Heart Failure, Acute Myeloid Leukemia and other specialties. Baylor University Medical Center is involved with conducting 357 clinical trials across 591 conditions. There are 17 research doctors associated with this hospital, such as Joyce O'Shaughnessy, MD, Carlos R Becerra, Susan Mathai, MD, and Andrew S Paulson, MD.Area of expertise
1Adult T-Cell Leukemia/Lymphoma
Global LeaderCD19 positive
Philadelphia chromosome positive
KMT2A positive
2Lymphoma
Global LeaderCD19 positive
CD20 positive
TP53 positive
Top PIs
Joyce O'Shaughnessy, MDTexas Oncology-Baylor Charles A. Sammons Cancer Center8 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
20 reported clinical trials
37 drugs studied
Carlos R BecerraGSK Investigational Site1 year of reported clinical research
Studies Solid Tumors
Studies Esophageal Cancer
6 reported clinical trials
10 drugs studied
Susan Mathai, MDBaylor Scott & White Research Institute1 year of reported clinical research
Studies Pulmonary Fibrosis
Studies Intestinal Fibrosis
5 reported clinical trials
7 drugs studied
Andrew S Paulson, MDTexas Oncology - Baylor Charles A. Sammons Cancer Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
5 reported clinical trials
9 drugs studied
Clinical Trials running at Baylor University Medical Center
Multiple Myeloma
Lymphoma
Idiopathic Pulmonary Fibrosis
Non-Hodgkin's Lymphoma
Myelodysplastic Syndrome
Heart Failure
Fibrosing Alveolitis
Fibrosing Colonopathy
Adult T-Cell Leukemia/Lymphoma
Acute Myeloid Leukemia
Elranatamab Combinations
for Multiple Myeloma
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Recruiting2 awards Phase 36 criteria
Daratumumab
for Multiple Myeloma
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Recruiting2 awards Phase 36 criteria
Elranatamab
for Multiple Myeloma
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Baylor University Medical Center?
Where is Baylor University Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Baylor University Medical Center accept?
What awards or recognition has Baylor University Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.